ES2239953T3 - Tratamiento del carcinoma de celulas renales. - Google Patents

Tratamiento del carcinoma de celulas renales.

Info

Publication number
ES2239953T3
ES2239953T3 ES00107100T ES00107100T ES2239953T3 ES 2239953 T3 ES2239953 T3 ES 2239953T3 ES 00107100 T ES00107100 T ES 00107100T ES 00107100 T ES00107100 T ES 00107100T ES 2239953 T3 ES2239953 T3 ES 2239953T3
Authority
ES
Spain
Prior art keywords
alpha
interferon
use according
pegylated
pegylated interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00107100T
Other languages
English (en)
Spanish (es)
Inventor
Esther Helen Rose
Mary Ellen Rybak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2239953T3 publication Critical patent/ES2239953T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES00107100T 1999-04-08 2000-04-06 Tratamiento del carcinoma de celulas renales. Expired - Lifetime ES2239953T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08
US288359 1999-04-08

Publications (1)

Publication Number Publication Date
ES2239953T3 true ES2239953T3 (es) 2005-10-16

Family

ID=23106761

Family Applications (2)

Application Number Title Priority Date Filing Date
ES00107100T Expired - Lifetime ES2239953T3 (es) 1999-04-08 2000-04-06 Tratamiento del carcinoma de celulas renales.
ES05002952T Expired - Lifetime ES2319777T3 (es) 1999-04-08 2000-04-06 Tratamiento de carcinoma de celulas renales.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES05002952T Expired - Lifetime ES2319777T3 (es) 1999-04-08 2000-04-06 Tratamiento de carcinoma de celulas renales.

Country Status (23)

Country Link
EP (2) EP1043025B1 (https=)
JP (2) JP3712914B2 (https=)
CN (1) CN1367702A (https=)
AR (1) AR029160A1 (https=)
AT (2) ATE296638T1 (https=)
AU (2) AU777406B2 (https=)
BR (1) BR0009644A (https=)
CA (1) CA2303752A1 (https=)
CO (1) CO5170412A1 (https=)
CY (1) CY1108919T1 (https=)
DE (2) DE60041291D1 (https=)
DK (2) DK1043025T3 (https=)
ES (2) ES2239953T3 (https=)
HU (1) HU230271B1 (https=)
MX (1) MXPA00003401A (https=)
MY (1) MY155221A (https=)
NO (1) NO328983B1 (https=)
NZ (1) NZ514629A (https=)
PE (1) PE20010026A1 (https=)
PT (2) PT1043025E (https=)
TW (2) TWI310314B (https=)
WO (1) WO2000061174A2 (https=)
ZA (1) ZA200108169B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2303752A1 (en) * 1999-04-08 2000-10-08 Schering Corporation Renal cell carcinoma treatment
CA2648077A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
ES2891564T3 (es) 2010-04-01 2022-01-28 Oncorena Ab Tratamiento mejorado del carcinoma de células renales
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
WO2024186735A1 (en) * 2023-03-03 2024-09-12 Memorial Sloan-Kettering Cancer Center Methods and compositions for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
WO1999048535A1 (en) * 1998-03-26 1999-09-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
CA2303752A1 (en) * 1999-04-08 2000-10-08 Schering Corporation Renal cell carcinoma treatment

Also Published As

Publication number Publication date
HK1032533A1 (en) 2001-07-27
JP2001288110A (ja) 2001-10-16
DK1535623T3 (da) 2009-04-27
ZA200108169B (en) 2003-01-06
MY155221A (en) 2015-09-30
CA2303752A1 (en) 2000-10-08
JP2000319196A (ja) 2000-11-21
EP1535623A1 (en) 2005-06-01
NO20014851L (no) 2001-12-07
TWI310314B (en) 2009-06-01
DE60020442D1 (de) 2005-07-07
NZ514629A (en) 2004-02-27
CN1367702A (zh) 2002-09-04
HUP0200781A2 (en) 2002-08-28
DE60020442T2 (de) 2006-05-04
AU2004242454A1 (en) 2005-01-20
CO5170412A1 (es) 2002-06-27
DE60041291D1 (de) 2009-02-12
EP1043025A3 (en) 2000-12-20
TW200526243A (en) 2005-08-16
NO328983B1 (no) 2010-07-05
JP3712914B2 (ja) 2005-11-02
CY1108919T1 (el) 2014-07-02
EP1043025A2 (en) 2000-10-11
WO2000061174A2 (en) 2000-10-19
NO20014851D0 (no) 2001-10-05
HU230271B1 (hu) 2015-11-30
AU2004242454B2 (en) 2007-02-15
AR029160A1 (es) 2003-06-18
BR0009644A (pt) 2002-01-08
JP4721488B2 (ja) 2011-07-13
HK1075417A1 (en) 2005-12-16
AU777406B2 (en) 2004-10-14
DK1043025T3 (da) 2005-07-04
PT1535623E (pt) 2009-03-19
PE20010026A1 (es) 2001-02-05
HUP0200781A3 (en) 2002-09-30
MXPA00003401A (es) 2002-03-08
ATE419002T1 (de) 2009-01-15
ATE296638T1 (de) 2005-06-15
AU4204400A (en) 2000-11-14
PT1043025E (pt) 2005-09-30
WO2000061174A3 (en) 2001-01-25
EP1043025B1 (en) 2005-06-01
ES2319777T3 (es) 2009-05-12
EP1535623B1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
ES2239953T3 (es) Tratamiento del carcinoma de celulas renales.
US6362162B1 (en) CML Therapy
US6605273B2 (en) Renal cell carcinoma treatment
JP2001288110A6 (ja) 腎細胞ガン処置
ES2319776T3 (es) Terapia de melanoma.
ES2243166T3 (es) Terapia de la leucemia mieloide cronica (cml).
HK1032533B (en) Renal cell carcinoma treatment
HK1075417B (en) Renal cell carcinoma treatment
JP2001288109A (ja) 黒色腫治療
HK1032348B (en) Chronic myeloid leukemia (cml) therapy
HK1075418A (en) Chronic myeloid leukemia (cml) therapy